© 2017 Kalim et al . This work is published and licensed by Dove Medical Press Limited . The full terms of this license are available at https : / / www . dovepress . com / terms . php and incorporate the Creative Commons Attribution – Non Commercial ( unported , v3 . 0 ) License ( http : / / creativecommons . org / licenses / by - nc / 3 . 0 / ) . By accessing the work you hereby accept the Terms . Non - commercial uses of the work are permitted without any further permission from Dove Medical Press Limited , provided the work is properly attributed . For permission for commercial use of this work , please see paragraphs 4 . 2 and 5 of our Terms ( https : / / www . dovepress . com / terms . php ) . Drug Design , Development and Therapy 2017 : 11 2265 – 2276 Drug Design , Development and Therapy Dovepress submit your manuscript | www . dovepress . com Dovepress 2265 R e v i e w open access to scientific and medical research Open Access Full Text Article http : / / dx . doi . org / 10 . 2147 / DDDT . S135571 Intracellular trafficking of new anticancer therapeutics : antibody – drug conjugates Muhammad Kalim 1 Jie Chen 1 Shenghao wang 1 Caiyao Lin 1 Saif Ullah 1 Keying Liang 1 Qian Ding 1 Shuqing Chen 2 Jinbiao Zhan 1 1 Department of Biochemistry and Genetics , School of Medicine , 2 Department of Pharmaceutical Analysis , College of Pharmaceutical Science , Zhejiang University , Hangzhou , People’s Republic of China Abstract : Antibody – drug conjugate ( ADC ) is a milestone in targeted cancer therapy that comprises of monoclonal antibodies chemically linked to cytotoxic drugs . Internalization of ADC takes place via clathrin - mediated endocytosis , caveolae - mediated endocytosis , and pinocytosis . Conjugation strategies , endocytosis and intracellular trafficking optimization , linkers , and drugs chemistry present a great challenge for researchers to eradicate tumor cells successfully . This inventiveness of endocytosis and intracellular trafficking has given consi - derable momentum recently to develop specific antibodies and ADCs to treat cancer cells . It is significantly advantageous to emphasize the endocytosis and intracellular trafficking pathways efficiently and to design potent engineered conjugates and biological entities to boost efficient therapies enormously for cancer treatment . Current studies illustrate endocytosis and intracel - lular trafficking of ADC , protein , and linker strategies in unloading and also concisely evaluate practically applicable ADCs . Keywords : antibody – drug conjugate , antibody , endocytosis , intracellular trafficking , clathrin Introduction Antibody – drug conjugate ( ADC ) is a milestone novel class of therapeutic agents in targeted cancer therapy . ADCs combine the antigenic specificity of an antibody with the assistance of potent tumorigenic effects of cytotoxic compounds . Traditionally , chemotherapeutic procedures have for quite some time been in practice to help dis - tinctive tumors treatment . However , targeted cancer therapy gained major interest in anticancer therapeutics that convey highly cytotoxic drugs directly to a tumor site . This approach of antibody - mediated drug delivery elevates maximum tolerance and has gained a considerable momentum in cancer therapy with the recent approval of two ADCs by the US Food and Drug Administration ( FDA ) , Kadcyla and Adcetris , along with . 40 conjugates in clinical trials . 1 Kadcyla , comprised of monoclonal antibody ( mAb ) , Herceptin , conjugated by means of lysine residue to DM1 that hinders cell division . 2 Adcetris comprised the cAC10 , a human – mouse chimeric antibody , through monomethyl auristatin E ( MMAE ) , a cysteine residue that inhibits tubulin polymeriza - tion . 3 These conjugates provide a unique opening of studying the mechanism of ADC action with tumor biology and cancer indication in drug development . Cells constantly internalize extracellular molecules to lumen and degrade through complex enzymatic pathways . This inventiveness of endocytosis and intracellular traf - ficking has given considerable momentum recently to develop specific antibodies and ADCs to treat cancer cells . It is profitable to accentuate endocytosis and intracellular trafficking pathways successfully for ADC design . This evolving approach of targeted therapy was because of the Ehrlich concept of “magic bullet” . 4 , 5 Further maturity of Correspondence : Jinbiao Zhan Department of Biochemistry and Genetics , School of Medicine , Zhejiang University , 866 Yuhangtang Road , Hangzhou , People’s Republic of China Tel + 86 571 8820 8272 Fax + 86 571 8820 8273 email jzhan2k @ zju . edu . cn Journal name : Drug Design , Development and Therapy Article Designation : Review Year : 2017 Volume : 11 Running head verso : Kalim et al Running head recto : Intracellular trafficking of ADC DOI : http : / / dx . doi . org / 10 . 2147 / DDDT . S135571 D r ug D e s i gn , D e v e l op m en t and T he r ap y do w n l oaded f r o m h tt p s : / / www . do v ep r e ss . c o m / b y 54 . 70 . 40 . 11 on 26 - A ug - 2019 F o r pe r s ona l u s e on l y . Powered by TCPDF ( www . tcpdf . org ) 1 / 1 Drug Design , Development and Therapy 2017 : 11 submit your manuscript | www . dovepress . com Dovepress Dovepress 2266 Kalim et al hybridoma technology by Kohler and Milstein 6 in 1975 and recent advancements in antibody engineering , significantly enlighten the field of ADCs production . Designing of ADC occurs in such a way that mimics toxicity of drugs and augments the antitumor activity of potent payloads , by inhibiting tubulin ( eg , auristatin , may - tansinoids ) , double - stranded DNA break , or minor groove binder / alkylators of DNA ( eg , ducomycin ) 7 , 8 as shown in Table 1 . These drugs are mostly derived from the natural source that triggers cell cycle arrest followed by apoptosis . Naito et al 9 reported morphological changes before cell arrest at a G2 / M phase in CD33 - positive acute myeloid cells by using calicheamicin - 676 drug . Despite numerous reports on drugs cytotoxicity , the intracellular trafficking studies of ADCs are still unclear . Current studies summarize knowledge of endocytosis and trafficking mechanism of ADCs with the current approach of their action . Endocytosis and trafficking of ADC ADC comprised of an mAb , linker , and cytotoxic payloads . The antibody counterpart binds specifically with target anti - gen on the tumor cell surface . Different features of antibody enhance optimization of ADC as summarized in Figure 1 . Physical and chemical properties of these conjugates are briefly studied in literature but degradation and intracellular trafficking properties of ADC are relatively unknown . 10 Successful optimization and development of ADC largely depend on its building units , tumor biology , antigen presen - tation , binding site chemistry , linker stability and its types , payload potency of loading drug , and drug – antibody ratio ( DAR ) . 11 – 13 Ideally , ADC must have selectivity , effective lytic nature , and ability to release its guided drug in active form to deliver optimum potency in killing cancerous cells . Antigen expression level is a key and dynamic parameter for initiation of putative results , as it will determine how Table 1 Different compounds and their targets used in ADCs optimization Names / compounds Targets Modes of action References Maytansinoid conjugates Microtubules Microtubule dynamics interference and G2 / M cell cycle arrest , resulting in cell death 112 Auristatin derivatives Microtubules Suppression and de - polymerization of microtubule dynamics 7 Calicheamicin derivatives Minor groove of DNA ( TCCT - rich region ) Binding with minor groove of DNA , resulting in dsDNA break and cell death 113 Duocarmycin ( MDX - 1203 , CC - 1065 ) Minor groove of DNA ( AT - rich sequences ) Alkylation of adenine 114 Vinca alkaloids / taxoids ( vincristine / vinblastine ) Tubulin binding Microtubule dynamics interference 7 , 115 Anthracycline drugs ( doxorubicin / nemorubicin / daunorubicin ) Tubulin binding Re - ligation inhibition and double strand break in DNA , resulting in cell death 116 , 117 Abbreviations : ADC , antibody – drug conjugate ; dsDNA , double - stranded DNA ; A , adenine ; C , cytosine ; T , thymine . Figure 1 Significant and dynamic characteristics of ADC . Notes : ( A ) Antibody , ( B ) linker , and ( C ) cytotoxic drug are three milestones in ADC optimization . Abbreviations : ADC , antibody – drug conjugate ; mAb , monoclonal antibody . (cid:38) (cid:82) (cid:81) (cid:73) (cid:82) (cid:85) (cid:80) (cid:68) (cid:87) (cid:76) (cid:82) (cid:81) (cid:68) (cid:79) (cid:86) (cid:87) (cid:68) (cid:69) (cid:76) (cid:79) (cid:76) (cid:87) (cid:92) (cid:37) (cid:76) (cid:86) (cid:83) (cid:72) (cid:70) (cid:76) (cid:73) (cid:76) (cid:70) (cid:38) (cid:92) (cid:87) (cid:82) (cid:87) (cid:82) (cid:91) (cid:76) (cid:70) (cid:76) (cid:87) (cid:92) (cid:40) (cid:73)(cid:73) (cid:72) (cid:70) (cid:87) (cid:76) (cid:89) (cid:72) (cid:38) (cid:76) (cid:85) (cid:70) (cid:88) (cid:79) (cid:68) (cid:87) (cid:76) (cid:82)(cid:81) (cid:86) (cid:87) (cid:68)(cid:69) (cid:76)(cid:79)(cid:76) (cid:87) (cid:92) (cid:37) (cid:76) (cid:81)(cid:71) (cid:76) (cid:81)(cid:74) (cid:86) (cid:83) (cid:72) (cid:70) (cid:76) (cid:73) (cid:76) (cid:70) (cid:76) (cid:87) (cid:92) (cid:68)(cid:81)(cid:71) (cid:3) (cid:68) (cid:73)(cid:73) (cid:76) (cid:81) (cid:76) (cid:87) (cid:92) (cid:80)(cid:36)(cid:69) (cid:47)(cid:76)(cid:81)(cid:78)(cid:72)(cid:85) (cid:177)(cid:3)(cid:38)(cid:79)(cid:72)(cid:68)(cid:89)(cid:68)(cid:69)(cid:79)(cid:72) (cid:177)(cid:3)(cid:36)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:85)(cid:72)(cid:79)(cid:72)(cid:68)(cid:86)(cid:72) (cid:177)(cid:3)(cid:39)(cid:76)(cid:86)(cid:88)(cid:79)(cid:73)(cid:76)(cid:71)(cid:72) (cid:177)(cid:3)(cid:43)(cid:92)(cid:71)(cid:85)(cid:68)(cid:93)(cid:82)(cid:81)(cid:72) (cid:177)(cid:3)(cid:51)(cid:72)(cid:83)(cid:87)(cid:76)(cid:71)(cid:72)(cid:18)(cid:83)(cid:85)(cid:82)(cid:87)(cid:72)(cid:68)(cid:86)(cid:72) (cid:177)(cid:3)(cid:54)(cid:87)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:76)(cid:81)(cid:3)(cid:70)(cid:76)(cid:85)(cid:70)(cid:88)(cid:79)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:79)(cid:82)(cid:81)(cid:74)(cid:16)(cid:87)(cid:72)(cid:85)(cid:80)(cid:3)(cid:86)(cid:87)(cid:82)(cid:85)(cid:68)(cid:74)(cid:72) (cid:177)(cid:3)(cid:57)(cid:76)(cid:87)(cid:85)(cid:82)(cid:3)(cid:83)(cid:82)(cid:87)(cid:72)(cid:81)(cid:70)(cid:92) (cid:177)(cid:3)(cid:55)(cid:88)(cid:80)(cid:82)(cid:85)(cid:16)(cid:86)(cid:83)(cid:72)(cid:70)(cid:76)(cid:73)(cid:76)(cid:70)(cid:3)(cid:86)(cid:72)(cid:81)(cid:86)(cid:76)(cid:87)(cid:76)(cid:89)(cid:76)(cid:87)(cid:92) (cid:177)(cid:3)(cid:58)(cid:68)(cid:87)(cid:72)(cid:85)(cid:3)(cid:86)(cid:82)(cid:79)(cid:88)(cid:69)(cid:79)(cid:72) (cid:177)(cid:3)(cid:39)(cid:49)(cid:36)(cid:3)(cid:70)(cid:79)(cid:72)(cid:68)(cid:89)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:74)(cid:72)(cid:81)(cid:87)(cid:38)(cid:68)(cid:79)(cid:76)(cid:70)(cid:75)(cid:72)(cid:68)(cid:80)(cid:76)(cid:70)(cid:76)(cid:81)(cid:86)(cid:39)(cid:88)(cid:82)(cid:70)(cid:68)(cid:85)(cid:80)(cid:92)(cid:70)(cid:76)(cid:81)(cid:86) (cid:177)(cid:3)(cid:48)(cid:76)(cid:70)(cid:85)(cid:82)(cid:87)(cid:88)(cid:69)(cid:88)(cid:79)(cid:76)(cid:81)(cid:3)(cid:76)(cid:81)(cid:75)(cid:76)(cid:69)(cid:76)(cid:87)(cid:82)(cid:85)(cid:3)(cid:3)(cid:36)(cid:88)(cid:85)(cid:76)(cid:86)(cid:87)(cid:68)(cid:87)(cid:76)(cid:81)(cid:86)(cid:3)(cid:3)(cid:48)(cid:68)(cid:92)(cid:87)(cid:68)(cid:81)(cid:86)(cid:76)(cid:81)(cid:86) (cid:38)(cid:92)(cid:87)(cid:82)(cid:87)(cid:82)(cid:91)(cid:76)(cid:70)(cid:3)(cid:71)(cid:85)(cid:88)(cid:74) (cid:36) (cid:37) (cid:38) D r ug D e s i gn , D e v e l op m en t and T he r ap y do w n l oaded f r o m h tt p s : / / www . do v ep r e ss . c o m / b y 54 . 70 . 40 . 11 on 26 - A ug - 2019 F o r pe r s ona l u s e on l y . Powered by TCPDF ( www . tcpdf . org ) 1 / 1 Drug Design , Development and Therapy 2017 : 11 submit your manuscript | www . dovepress . com Dovepress Dovepress 2267 Intracellular trafficking of ADC much ADC will bind to the cancerous cell and internalize . Low expression level limits the binding and inadequate endocytosis , thereby restricting efficient delivery of ADC - loaded drug . 14 Endocytosis can be manifested by different internalization routes such as clathrin - mediated , caveolae - mediated , and clathrin – caveolin - independent endocytosis 15 ( Figure 2 ) , but much work has been focused on clathrin - mediated endocyto - sis ( CME ) . The first two are receptor - mediated endocytosis , while the latter one is receptor - independent endocytosis . High binding interaction of antigen – antibody results in accumulation of more ADCs on the membrane surface . It is hard to distinguish among these pathways as some molecules are not restricted to a single pathway . CME was reported as the central route adopted by various ADCs . Trafficking of ADCs occurs with the aid of adaptor pro - tein ( AP2 ) , dynamin , epsin , and phosphatidylinositol ( 4 , 5 ) bi - phosphate ( PIP2 ) . 16 Precise ligands accomplished binding activity of antigen and antibody on tumor surface more actively . These ligands include protein molecules , small molecular receptors , antibodies , peptides and proteins , and carbohydrates . 17 – 19 The most prominent among these are target - specific mAb fragments , 20 transferrin , 21 peptides , 22 and folate . 23 Endocytosis of tiny , unionized hydrophobic molecules occurs passively , while large , charged polar , or conjugated molecules are car - ried inside in the form of complex coordinated pathways by utilization of energy - rich sources . 24 – 26 The most prominent recruitment pathway reported for transportation is clathrin - mediated by the formation of clathrin - coated vesicles ( CCVs ) or membrane invagination coats that cover 2 % total area . 27 , 28 The other less prominent pathways including caveolin - mediated , 29 clathrin – caveolin - independent , 30 and cholesterol / macropinocytosis - mediated are also reported in literature . 31 Mayor et al also reported that other small caveolae vesicles contain lipid microdomain involved in different transduction events with lack of clathrin protein function . 32 After passing membrane barriers , conjugate marched toward endosomes and emptied there with indication of prominent markers , ie , Rab 5 , Rab 7 and Rab 11 . 33 , 34 Figure 2 Different endocytosis routes followed by ADC . Notes : Endocytosis of ADC takes place through three different mechanisms , ie , CME , caveolin - mediated endocytosis , and clathrin – caveolin - independent endocytosis . ADC conjugates travel inside and reach endosome / lysosome lumen , where it reloads its payloads and targets cell binary structures to rupture tumor cell . Abbreviations : ADC , antibody – drug conjugate ; CaMe , caveolin - mediated endocytosis ; CMe , clathrin - mediated endocytosis ; CCie , clathrin – caveolin - independent endocytosis ; CCP , clathrin - coated pits ; CDC , cell division cycle ; ee , early endosome ; ePS15 , epidermal growth factor receptor substrate 15 ; Le , late endosome ; mono - Ub , mono - ubiquitylation ; MVB , multivesicular antibody ; PKC , protein kinase C ; RAC1 , Ras - related C3 botulinum toxin substrate 1 ; RE , recycling endosome ; SRC , Rous sarcoma virus cellular protein ; TK , tyrosine kinase . (cid:38)(cid:79)(cid:68)(cid:87)(cid:75)(cid:85)(cid:76)(cid:81) (cid:38)(cid:38)(cid:51) (cid:38)(cid:68)(cid:89)(cid:72)(cid:82)(cid:79)(cid:82)(cid:86)(cid:82)(cid:80)(cid:72) (cid:47)(cid:92)(cid:86)(cid:82)(cid:86)(cid:82)(cid:80)(cid:72) (cid:47)(cid:40)(cid:18)(cid:48)(cid:57)(cid:37) (cid:40)(cid:40) (cid:53)(cid:40) (cid:51)(cid:76)(cid:81)(cid:82)(cid:86)(cid:82)(cid:80)(cid:72) (cid:57)(cid:72)(cid:86)(cid:76)(cid:70)(cid:79)(cid:72) (cid:38) (cid:79) (cid:68) (cid:87) (cid:75) (cid:85) (cid:76) (cid:81) (cid:16) (cid:3) (cid:68)(cid:81)(cid:71) (cid:3) (cid:70) (cid:68) (cid:89) (cid:72)(cid:82) (cid:79)(cid:76) (cid:81) (cid:16) (cid:76) (cid:81)(cid:71)(cid:72)(cid:83)(cid:72)(cid:81)(cid:71)(cid:72)(cid:81) (cid:87)(cid:3) (cid:72)(cid:81)(cid:71)(cid:82) (cid:70)(cid:92) (cid:87) (cid:82) (cid:86) (cid:76) (cid:86) (cid:51) (cid:85) (cid:82) (cid:87) (cid:72) (cid:76) (cid:81) (cid:86) (cid:3) (cid:76) (cid:81) (cid:38)(cid:38) (cid:44) (cid:40) (cid:3) (cid:85) (cid:72)(cid:74)(cid:88) (cid:79) (cid:68) (cid:87) (cid:76) (cid:82)(cid:81) (cid:51) (cid:85) (cid:82) (cid:87) (cid:72) (cid:76) (cid:81) (cid:86) (cid:3) (cid:76) (cid:81) (cid:38) (cid:48) (cid:40) (cid:3) (cid:85) (cid:72) (cid:74) (cid:88) (cid:79) (cid:68) (cid:87) (cid:76) (cid:82) (cid:81) (cid:38) (cid:79) (cid:68) (cid:87) (cid:75) (cid:85) (cid:76) (cid:81) (cid:3) (cid:80) (cid:72)(cid:71) (cid:76) (cid:68) (cid:87) (cid:72)(cid:71) (cid:53) (cid:72) (cid:70) (cid:72)(cid:83) (cid:87) (cid:82) (cid:85)(cid:16) (cid:80) (cid:72)(cid:71) (cid:76) (cid:68) (cid:87) (cid:72)(cid:71) (cid:3) (cid:72)(cid:81)(cid:71)(cid:82) (cid:70)(cid:92) (cid:87) (cid:82) (cid:86) (cid:76) (cid:86) (cid:38) (cid:68) (cid:89) (cid:72)(cid:82) (cid:79)(cid:76) (cid:81) (cid:3) (cid:80) (cid:72)(cid:71) (cid:76) (cid:68) (cid:87) (cid:72)(cid:71) (cid:51) (cid:85) (cid:82) (cid:87) (cid:72) (cid:76) (cid:81) (cid:86) (cid:3) (cid:76) (cid:81) (cid:38) (cid:68) (cid:48) (cid:40) (cid:3) (cid:85) (cid:72)(cid:74)(cid:88) (cid:79) (cid:68) (cid:87) (cid:76) (cid:82)(cid:81) (cid:53)(cid:36)(cid:38)(cid:80)(cid:82)(cid:81)(cid:82)(cid:16)(cid:56)(cid:69)(cid:40)(cid:51)(cid:54)(cid:20)(cid:24)(cid:40)(cid:83)(cid:86)(cid:76)(cid:81)(cid:86)(cid:53)(cid:68)(cid:69)(cid:24)(cid:36)(cid:55)(cid:46) (cid:53) (cid:36) (cid:38) (cid:20) (cid:53) (cid:88) (cid:73)(cid:73) (cid:79) (cid:72) (cid:86) (cid:53) (cid:68)(cid:69)(cid:24)(cid:22) (cid:38)(cid:39)(cid:38) (cid:23)(cid:21) (cid:36) (cid:53) (cid:41) (cid:25) (cid:49) (cid:72) (cid:91) (cid:76) (cid:81) (cid:53)(cid:75)(cid:82)(cid:36)(cid:36)(cid:51)(cid:21)(cid:39)(cid:92)(cid:81)(cid:68)(cid:80)(cid:76)(cid:81) (cid:39) (cid:92) (cid:81)(cid:68) (cid:80) (cid:76) (cid:81) (cid:51)(cid:46) (cid:38) (cid:44) (cid:81) (cid:87) (cid:72) (cid:85) (cid:86) (cid:72) (cid:70) (cid:87) (cid:76) (cid:81) (cid:54) (cid:53)(cid:38) (cid:55)(cid:88)(cid:69)(cid:88)(cid:79)(cid:68)(cid:85) (cid:38)(cid:68)(cid:89)(cid:72)(cid:82)(cid:79)(cid:76)(cid:81) D r ug D e s i gn , D e v e l op m en t and T he r ap y do w n l oaded f r o m h tt p s : / / www . do v ep r e ss . c o m / b y 54 . 70 . 40 . 11 on 26 - A ug - 2019 F o r pe r s ona l u s e on l y . Powered by TCPDF ( www . tcpdf . org ) 1 / 1 Drug Design , Development and Therapy 2017 : 11 submit your manuscript | www . dovepress . com Dovepress Dovepress 2268 Kalim et al Early endosome becomes late endosome by losing protein which plays the vital role in recycling . The decrease in pH occurs by utilization of proton pump . 35 Late endosome fuses with lysosome resulting in pH decrease . ADCs’ degradation occurs due to acidic environment and enzymatic activities of lysosome . 36 , 37 Recycling of membrane proteins and lipid occurs through the complex process by utilization of Rab proteins / GTPases to regulate mechanism of endocytosis and proteins balance at the membrane surface . 33 , 34 , 38 CME and caveolin - mediated endocytosis utilized Rab 11 protein to recycle back ADC . 34 Nexinprotein performs this recycling activity from the endo - some toward the membrane surface . 33 , 39 Time optimization of recurring changes after 1 hour of endocytosis . The ADC - carrying payload reaches the lysosome and releases the drug due to a breakage of a linker . The free payloads reach the targeted area resulting in a disruption of tubules or cell cycle arrest , which ultimately results in apoptosis of the cancer cell as shown in Figure 3 . Protein machinery in endocytosis ADCs travel inside the cell via the bucket of clathrin - coated pits , become uncoated by the Hsp70 protein complex , and fuse with early endosomes to acquire the endosomal – lysosomal trafficking . 39 ATP - dependent proton pump exists in endo - some and lysosome and changes the pH of early endosomes ( 6 . 0 – 6 . 2 ) , late endosomes ( 5 . 5 ) , and lysosomes ( 4 . 5 – 5 . 0 ) . 40 The acidification results in dissociation of ligands , such as insulin , epidermal growth factor ( EGF ) , and low - density lipoprotein ( LDL ) from receptors in early endosomes , and vacant receptors get into surface membrane via recycling compartment of narrow tubules . Several kinds of literature reported an alternative set of protein machinery that led to the formation of the same morphological structures as in the case of endocytic tubes and caveolae . 41 A progress report conducted by Sabharanjak et al 42 in Satyajit Mayor ( National Center for Bio Science , Bangalore ) characterized clathrin - , dynamin - , and caveolae - independent internalization path - ways for transportation of glycosylphosphatidylinositol Figure 3 Mechanism of endocytosis and intracellular trafficking of ADC . Notes : ( A ) Shows surface localization of antigen – antibody complex , ( B ) shows mechanism of endocytosis , and ( C ) indicates final cell death of tumor cell . Abbreviations : ADC , antibody – drug conjugate ; CMe , clathrin - mediated endocytosis ; ee , early endosome ; FcRn , neonatal Fc receptor ; Le , late endosome . (cid:36)(cid:39)(cid:38) (cid:36)(cid:81)(cid:87)(cid:76)(cid:74)(cid:72)(cid:81) (cid:20)(cid:17)(cid:3)(cid:38)(cid:76)(cid:85)(cid:70)(cid:88)(cid:79)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:36)(cid:39)(cid:38)(cid:76)(cid:81)(cid:3)(cid:69)(cid:79)(cid:82)(cid:82)(cid:71)(cid:3)(cid:86)(cid:87)(cid:85)(cid:72)(cid:68)(cid:80) (cid:36)(cid:39)(cid:38) (cid:24)(cid:17)(cid:3)(cid:53)(cid:72)(cid:70)(cid:92)(cid:70)(cid:79)(cid:72)(cid:3)(cid:36)(cid:39)(cid:38)(cid:3)(cid:80)(cid:82)(cid:79)(cid:72)(cid:70)(cid:88)(cid:79)(cid:72)(cid:86)(cid:3)(cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:83)(cid:82)(cid:85)(cid:87)(cid:72)(cid:71)(cid:3)(cid:69)(cid:68)(cid:70)(cid:78)(cid:3)(cid:82)(cid:88)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:70)(cid:72)(cid:79)(cid:79) (cid:47)(cid:92)(cid:86)(cid:82)(cid:86)(cid:82)(cid:80)(cid:72)(cid:86) (cid:25)(cid:17)(cid:3)(cid:47)(cid:40)(cid:47)(cid:92)(cid:86)(cid:82)(cid:86)(cid:82)(cid:80)(cid:72)(cid:86)(cid:3)(cid:85)(cid:72)(cid:79)(cid:72)(cid:68)(cid:86)(cid:72)(cid:72)(cid:81)(cid:93)(cid:92)(cid:80)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:87)(cid:82)(cid:3)(cid:47)(cid:40)(cid:3)(cid:85)(cid:72)(cid:86)(cid:88)(cid:79)(cid:87)(cid:86)(cid:88)(cid:81)(cid:69)(cid:76)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:73)(cid:3)(cid:70)(cid:92)(cid:87)(cid:82)(cid:87)(cid:82)(cid:91)(cid:76)(cid:70)(cid:71)(cid:85)(cid:88)(cid:74)(cid:86)(cid:3)(cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:36)(cid:39)(cid:38) (cid:49)(cid:88)(cid:70)(cid:79)(cid:72)(cid:88)(cid:86) (cid:38)(cid:92)(cid:87)(cid:82)(cid:87)(cid:82)(cid:91)(cid:76)(cid:70)(cid:3)(cid:71)(cid:85)(cid:88)(cid:74) (cid:26)(cid:17)(cid:3)(cid:36)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:39)(cid:76)(cid:86)(cid:85)(cid:88)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:80)(cid:76)(cid:70)(cid:85)(cid:82)(cid:87)(cid:88)(cid:69)(cid:88)(cid:79)(cid:72)(cid:82)(cid:85)(cid:3)(cid:39)(cid:49)(cid:36)(cid:3)(cid:85)(cid:72)(cid:86)(cid:88)(cid:79)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:70)(cid:72)(cid:79)(cid:79)(cid:3)(cid:78)(cid:76)(cid:79)(cid:79)(cid:76)(cid:81)(cid:74) (cid:27)(cid:17)(cid:3)(cid:38)(cid:72)(cid:79)(cid:79)(cid:3)(cid:71)(cid:72)(cid:68)(cid:87)(cid:75) (cid:38)(cid:92)(cid:87)(cid:82)(cid:87)(cid:82)(cid:91)(cid:76)(cid:70)(cid:3)(cid:71)(cid:85)(cid:88)(cid:74) (cid:41)(cid:70)(cid:53)(cid:81) (cid:38)(cid:79)(cid:68)(cid:87)(cid:75)(cid:85)(cid:76)(cid:81) (cid:39)(cid:92)(cid:81)(cid:68)(cid:80)(cid:76)(cid:81) (cid:22)(cid:17)(cid:3)(cid:40)(cid:81)(cid:71)(cid:82)(cid:70)(cid:92)(cid:87)(cid:82)(cid:86)(cid:76)(cid:86)(cid:53)(cid:72)(cid:70)(cid:72)(cid:83)(cid:87)(cid:82)(cid:85)(cid:16)(cid:80)(cid:72)(cid:71)(cid:76)(cid:68)(cid:87)(cid:72)(cid:71)(cid:72)(cid:81)(cid:71)(cid:82)(cid:70)(cid:92)(cid:87)(cid:82)(cid:86)(cid:76)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:36)(cid:39)(cid:38)(cid:3)(cid:11)(cid:38)(cid:48)(cid:40)(cid:12) (cid:21)(cid:17)(cid:3)(cid:37)(cid:76)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:73)(cid:3)(cid:36)(cid:39)(cid:38)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:68)(cid:81)(cid:87)(cid:76)(cid:74)(cid:72)(cid:81) (cid:36)(cid:81)(cid:87)(cid:76)(cid:74)(cid:72)(cid:81)(cid:18)(cid:36)(cid:39)(cid:38)(cid:70)(cid:82)(cid:80)(cid:83)(cid:79)(cid:72)(cid:91) (cid:23)(cid:17)(cid:3)(cid:40)(cid:40) (cid:55)(cid:85)(cid:68)(cid:73)(cid:73)(cid:76)(cid:70)(cid:78)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:73)(cid:3)(cid:36)(cid:39)(cid:38)(cid:86)(cid:3)(cid:87)(cid:82)(cid:40)(cid:40)(cid:3)(cid:90)(cid:75)(cid:72)(cid:85)(cid:72)(cid:3)(cid:86)(cid:82)(cid:80)(cid:72)(cid:3)(cid:36)(cid:39)(cid:38)(cid:74)(cid:72)(cid:87)(cid:3)(cid:69)(cid:68)(cid:70)(cid:78)(cid:3)(cid:87)(cid:82)(cid:3)(cid:80)(cid:72)(cid:80)(cid:69)(cid:85)(cid:68)(cid:81)(cid:72)(cid:86)(cid:88)(cid:85)(cid:73)(cid:68)(cid:70)(cid:72)(cid:3)(cid:89)(cid:76)(cid:68)(cid:3)(cid:41)(cid:70)(cid:53)(cid:81) (cid:38) (cid:92) (cid:87) (cid:82) (cid:87) (cid:82) (cid:91) (cid:76) (cid:70) (cid:71) (cid:85) (cid:88)(cid:74) (cid:36) (cid:38) (cid:37) D r ug D e s i gn , D e v e l op m en t and T he r ap y do w n l oaded f r o m h tt p s : / / www . do v ep r e ss . c o m / b y 54 . 70 . 40 . 11 on 26 - A ug - 2019 F o r pe r s ona l u s e on l y . Powered by TCPDF ( www . tcpdf . org ) 1 / 1 Drug Design , Development and Therapy 2017 : 11 submit your manuscript | www . dovepress . com Dovepress Dovepress 2269 Intracellular trafficking of ADC ( GPI ) - anchored proteins and an addition of early endosomal compartments ( GEEC ) as an intermediate protein . Chadda et al 43 also reported that cholesterol - dependent recruit - ment and active Cdc42 stabilization on the plasma surface membrane initiate the pinocytic pathway that led localized actin polymerization . Cdc42 is controlled by Arf1 , such as ARH - GAP10 and small GTPases , to regulate endocytosis . It was also reported that CME required adaptor proteins such as AP2 , EPS - 15 , and clathrin triskelion for the formation of clathrin - coated pits at the membrane surface . 44 , 45 Several pathways share the same requirements for dynamin and Arf6 ( ADP - ribosylation factor ) . Donaldson 46 also reported multiple roles of Arf6 in structure , signals , and membrane trafficking of a cell . Caveolae are generated by addition of a primary protein , caveolin , which is a specialized form of lipid rafts . 47 Caveolae become caveosome , a caveolin - enriched organelle , processed further by the endosome . Dynamin , protein kinase C , and Src kinases regulate the activation further . 48 Clathrin - and caveolin - independent endocytosis is mediated by different protein machineries such as dynamin , 49 CDC42 , ARF1 50 and ARF6 , 51 tyrosine kinases , 52 RacGTPases , and USP6NL . 53 These studies show a broad framework of internalization kinetics and its impact on provision of ADC to entire tumor mass . 16 Linker strategy and drug release Endocytosis and trafficking of ADCs by tumor cells are typically sorted by endosomal / lysosomal pathways . Many studies reported the active release of drugs in lysosome either by cleavage of the linker or by antibody backbone degradation . This release of drugs largely depends on linker design and its chemistry . Generally , linkers must have high stability in circulation and the ability to release a drug in the targeted regions of tumor cells . Currently four different types of linkers in use are broadly divided into cleavable and non - cleavable linkers . 54 Acid - labile hydrazine linkers , peptide linkers , and disulfide linkers are included in cleavable linkers . Acid - labile hydrazine linkers are cleaved in the lysosome compartment as a result of low pH . Unfortunately , acid labile hydrazine linkers have established off - target release in clini - cal examination . 55 , 56 Peptide linkers conceivably selective for cleavage in lysosome by activity of cathepsin B . 57 Unlike the hydrazine linker , peptide linkers show high serum stability and improved antitumor effects of ADC . Phe - Lys and Val - Cit are physiological stable peptide linkers but hydrolyze rapidly in the presence of enzymes . 58 The longer half - life of peptide linkers was recorded as compared to other cleavable linkers . 59 Disulfide linkers also raise questions of non - specific cytotoxicity and instability and off - target release of drugs . Recent advancement in linker technology has been covered by non - cleavable linkers . The chemical bond of non - cleavable linkers is highly stable in circulation and inside the cell . The release of an active potent drug inside a tumor cell is realized by degradation of antibodies in the lysosome . 57 More importantly , the recently approved ADC , trastuzumab - DM1 ( Kadcycla ) , also utilized non - cleavable linkers to treat metastatic breast cancer . More effective stud - ies were also reported in vivo analysis by using non - cleavable linkers compared to their disulfide counterpart . 60 , 61 The linker is one of the most vital components of ADCs that anchor cytotoxic drugs to an antibody . It must be stable in circulation and potent in effective drug release inside the cell to acquire maximal therapeutic windows . 62 Once inter - nalization was confirmed , it should be cleavable by enzymatic action or acidic change in lysosomes . Four different types of linkers were reported including disulfide and peptide base and acid cleavable and non - cleavable linkers . Three common strategies have been reported for a release of efficient drugs , ie , pH sensitivity , protease sensitivity , and glutathione sensi - tivity . The protease of lysosome recognizes a specific peptide sequence in the linker . 58 Lower pH of the endosome ( 5 . 0 – 6 . 0 ) and lysosome ( 4 . 8 ) , as compared to cytosolic pH ( 7 . 4 ) , elicits hydrolysis of a linker acid - labile group as in hydrazone . The third strategy of drug release exploits the higher ratio of intracellular glutathione as compared to plasma . 16 Early development of ADC was conducted by utilization of the hydrazine linker , but a major downfall in its produc - tivity , it undergoes spontaneous cleavage compared to dis - ulfide and peptide linkers , was reported . 63 These linkers are enzymatic in hydrolysis and can be selected for preferential expression , minimizing the spontaneous release of drugs in circulation . 56 , 64 Peptide linkers exhibit improved antitumor activity and stability , demonstrating bystander cytotoxicity . 65 Cytotoxic drugs endure modification by disulfide reduction to methylation and have access to neighboring cells , resulting in lyses . 66 This mechanism is very fruitful to eradicate the tumor cells that do not express the targeted antigen within the tumor cell . 67 , 68 Efficacy of antibody and linker technology can be elevated by making changes in binding sites to confer con - sistency of ADC . 69 , 70 Lyon et al 71 introduce a novel concept of maleimide linkers that catalyze their own thiosuccinimide ring hydrolysis , prevent drug loss , and develop a high stable ADC . King et al also reported a novel series of branched hydrazone linkers and made immune conjugates of mAbs BR96 and doxorubicin that were stable at pH 7 . These conjugates release DOX molecules at lysosomal pH . They concluded a possible outcome of using a reduced amount D r ug D e s i gn , D e v e l op m en t and T he r ap y do w n l oaded f r o m h tt p s : / / www . do v ep r e ss . c o m / b y 54 . 70 . 40 . 11 on 26 - A ug - 2019 F o r pe r s ona l u s e on l y . Powered by TCPDF ( www . tcpdf . org ) 1 / 1 Drug Design , Development and Therapy 2017 : 11 submit your manuscript | www . dovepress . com Dovepress Dovepress 2270 Kalim et al of mAb load via branched methodology to acquire desired cytotoxic activity . 72 Recently , specificity of HER2 antibodies and enhanced activity of doxorubicin - labeled liposomes against cancer were also reported by our research group . 73 However , poor circulation stability of hydrazine linker was also recorded as in the case of gemtuzumab ozogamicin ( GO ) , resulting in low clinical efficacy and safety . 74 On the other hand , premature release in circulation is being prevented by utilizing non - cleavable linkers . 56 Non - cleavable linkers result in enzymatic degradation of ADC in lysosome and accurate release of drug with their conjugated amino acid lysine or cysteine . 67 Active research by chemists to develop new linkers and discover novel potent effector molecules that suit ADC is currently being investigated . Co - localization of ADC Properties of cell surface proteins targeted by ADCs have not been fully exploited , of which the rate of internalization and the route of intracellular trafficking are of particular importance . Targeted delivery of anticancer drugs to tumor cells using mAb against cell surface receptors is an emerging therapeutic strategy . The rate of internalization was compared between ADCs with their antibodies , and similar effects were found as in the case of anti - CD30 ( cAC10 ) and the antimitotic agent , auristatin . 75 Similarly , it was also reported that conjugate of anti - MUC - 1 in breast and ovarian cancer xenografts , with DNA minor groove binder , calicheamicin , have the same endocytosis rate . 76 In contrast , some aurista - tin conjugates efficiently internalized as compared to their antibody moieties . Ingle et al reported the efficiency of both CD19 and CD21 , B cell surface receptors , and found that even at higher expressions of CD21 receptors , the ADC is unable to internalize . But the absence of CD21 results in efficient endocytosis of anti - CD19 ADC molecules . These receptor molecules develop a complex on B cell surfaces that mimics internalization of CD19 by CD21 . 77 Similarly , selective binding of antibodies contributes enormously in elevated endocytosis and potent toxicity of ADC . It was also recorded that there are no set parameters with optimal binding / internalization affinity , and maximum correlation of ADC and antibodies as strong binding results in faster internalization and efficient ADC trafficking . 55 These reports attract consideration extensively to acknowledge molecular mechanism of receptor mediated endocytosis and particular cell target properties while designing ADC . Law et al reported two different co - localization studies of anti - CD70 antibody and anti - CD20 with the anti - tubulin auristatin conjugate . Anti - CD70 conjugate followed CME and trafficked to the lysosome for payload release . The released payload , by the enzymatic activity of lysosomes , results in microtubule channels disruption and G2 / M cell cycle arrest in metastatic renal cell carcinoma ( RCC ) . 78 Anti - CD20 antibody and auristatin conjugate was carried by both CME and caveolin together . They used two anti - CD20 conjugates , rituximab - vcMMAE and 1F5 - vcMMAE , to selectively target B - lymphoma cell lines , trafficked to a cell . The enzymatic activity of lysosome results in linker destruc - tion , releasing the payload and eventually caused G2 / M phase arrest and apoptosis . 79 One pre - clinical study was conducted previously by our research group by targeting CD20 - positive B lymphoid malignancies , using ofatumumab auristatin con - jugate ofatumumab - valine citrullin - monomethyl auristatin ( OFA - vcMMAE ) , resulting in complete inhibition of CD20 - positive cells and exhibited enhanced activity as compared to unconjugated OFA . 80 Recently , Pan et al recorded conjuga - tion of TRAIL ( Tumor - Inducing Factor - Related Apoptosis Inducing Ligands ) with MMAE for efficient drug delivery to tumor cell . 81 Co - localization of auristatin and anti - melanotransferrin conjugate was also reported in melanoma - sensitive cell lines ( SK - MEL5 and A2058 ) and - resistant cell lines ( L49 - vcMMAE ) . 82 In sensitive cell lines , conjugate followed CME pathways for its endocytosis , while resistant cell lines utilized caveolin - II of caveolae to colonize the conjugate . One study revealed that inhibition of anti - CD30 – trastuzumab conjugate occurs by clathrin inhibitor and internalized by caveolae - mediated endocytosis to cell . 75 Acidic environment of endosome – lysosome slows down the trafficking of anti - CD30 , and its trastuzumab conjugate was also reported . 75 , 83 Higher concentration of ADCs in surrounding medium facilitates its endocytosis silently through the membrane surface as was reported in GO that non - specifically inhibits the CD33 - negative acute lymphoblastic leukemia cells , while the lower concentration of GO in surrounding medium results in triggering of CME pathway to take ADCs into CD33 - positive malignant cells . 84 The pinocytosis neither induces S - G2 / M cell arrest nor apoptosis but results from necrotic lyses . 85 However , the exact and precise quantification of ADC is still a topic of debate . These reports reveal different routes of ADC induction to the cell from surroundings and its trafficking to the targeted region of a cancer cell . ADCs in clinical use and their mechanism studies More than 100 different ADCs are in different stages of clinical evaluation , majority carrying microtubule disrupt - ing loads ( maytansinoids / auristatins ) . Subsequent para - graphs describe detailed assessment of different ADCs and D r ug D e s i gn , D e v e l op m en t and T he r ap y do w n l oaded f r o m h tt p s : / / www . do v ep r e ss . c o m / b y 54 . 70 . 40 . 11 on 26 - A ug - 2019 F o r pe r s ona l u s e on l y . Powered by TCPDF ( www . tcpdf . org ) 1 / 1 Drug Design , Development and Therapy 2017 : 11 submit your manuscript | www . dovepress . com Dovepress Dovepress 2271 Intracellular trafficking of ADC their intracellular trafficking . Only three ADCs obtained approval by FDA . Two of them employ effective tubulin - disrupting agents , either MMAE or maytansine derivatives ( DM1 ) , and the other one utilizes calicheamicin DNA strand - breaking agent as shown in Table 2 . The trafficking studies of these drugs are still unknown . One quantitative model study is available in current literature that describes cellular processing , trafficking mechanism , internalization rate , proteolytic degradation , and binding mechanism of trastuzumab – maytansinoid conjugate . 86 GO ( Mylotarg ) GO was the first ADC that gained marketing approval from FDA in 2000 . GO ( Mylotarg ) made conjugation with CD33 - positive cells by anti - CD30 counterpart and released its pay - load calicheamicin compound to cell lumen due to breakage of hydrazone linker . GO was subsequently withdrawn from the market in 2010 due to its toxicity and insufficient clinical results . 74 This conjugate got access to the cell through antigen - independent manner and was internalized from surrounding medium by pinocytosis and destroyed cells by necrotic lyses . 85 CME was also reported of GO , resulting in S - G2 / M cell cycle arrest and apoptosis of CD33 + acute myeloid leukemia cell . 84 Prostate specific membrane antigen conjugate valine citrullin - monomethyl auristatin ( PSMA - vcMMAe ) Prostate specific membrane antigen conjugate valine citrullin - monomethyl auristatin ( PSMA - vcMMAE ) is composed of fully human anti - PSMA mAb , conjugated with MMAE through cleavable valine – citrulline linker . 87 PSMA - vcMMAE Table 2 List of ADCs and their endocytosis and mode of action Names of ADCs Targets Linkers / drugs Status Entry routes / mechanism References Brentuximab vedotin ( Adcetris , SGN - 35 ) CD30 val - cit / MMAe Launched CMe / S - G2 / M arrest , tubulin inhibitor 75 , 92 Ado - trastuzumab ( Kadcyla , T - DM1 ) HeR2 Thioether / DM1 Launched RMe / microtubule disruption 95 inotuzumab ozogamicin ( CMC - 544 ) CD22 Hydrazone / calicheamicin withdrawn RMe / minor groove and dsDNA break 91 Gemtuzumab ozogamicin ( Mylotarg ) CD33 Hydrazone / calicheamicin withdrawn Pinocytosis / CMe / DNA cleavage 74 , 85 SAR3419 CD19 Disulfide / DM4 Ph ii RMe / microtubule disruption 104 RG7596 CD79b val - cit / MMAe Ph ii RMe / microtubule disruption 118 RG7593 / DCDT29805 CD22 Dipeptide / MMAe Ph ii RMe / microtubule disruption 119 Glembatumumab vedotin ( CDX - 011 ) GPNMB val - cit / MMAe Ph ii RMe / spindle degradation 110 PSMA - ADC PSMA val - cit / MMAe Ph ii RMe / tubulin disruption 87 BT - 062 CD138 Disulfide / DM1 Ph i RMe / microtubule disruption 103 Lorvotuzumab mertansine ( iMGN901 ) CD56 Disulfide / DM1 Ph i HeR3 / P13K / AKT signaling , apoptosis , cell death 105 Milatuzumab doxorubicin ( iMMU - 110 ) CD74 Hydrazone / doxorubicin Ph i RMe / re - ligation inhibition and dsDNA break 105 SAR566658 CA6 / DS6 Disulfide / DM4 Ph i RMe / microtubule disruption 120 BAY - 79 - 4620 CA - 1X val - cit / MMAe withdrawn Tubulin polymerization inhibitor , G2 / M arrest 121 BAY - 94 - 9343 Mesthelin Disulfide / DM4 Ph i RMe / microtubule disruption 122 SGN - 75 CD70 Maleimidocaproyl / MMAe Ph i RMe / tubulin inhibitor 123 , 124 Labetuzumab - SN - 38 CD66e / CeACAMS Phe - lys / SN - 38 Ph i / ii RMe / topoisomerase i inhibitor 125 MDX - 1203 CD70 val - cit / MGBA Ph i DNA break 126 BiiB015 Cripto Disulfide / DM4 withdrawn RMe / microtubule disruption 102 iMGN388 ( CNT0365 ) integrin Maytansinoid / DM4 withdrawn RMe / microtubule disruption 100 iMGN853 FR γ ( folate ) Disulfide - sulfo - SPDB / DM4 Ph i RMe / microtubule disruption 127 iMGN289 eGFR SMCC Thioether / DM1 Ph i RMe / microtubule disruption 128 SGN - CD33A CD33 Protease / PBD Ph i DNA minor groove cross - linker 70 AGS - 22Me Nectin 4 val - cit / MMAe Ph i RMe / tubulin inhibitor 129 iMGN529 CD37 Thioether / DM1 Ph i RMe / microtubule disruption 130 AGS - 5Me AGS - 5 val - cit / MMAe Ph i RMe / tubulin inhibitor 131 Abbreviations : ADC , antibody – drug conjugate ; CeACAMS , carcino embryonic antigen cell adhesion molecule ; CMe , clathrin - mediated endocytosis ; dsDNA , double - stranded DNA ; HeR2 , human epidermal growth factor receptor 2 ; MMAe , monomethyl auristatin e ; MMAF , monomethyl auristatin F ; PBD , pyrrolobenzodiazepine ; RMe , receptor - mediated endocytosis ; SPDB , N - succinimidyl - 3 - ( 2 - pyridyldithio ) butyrate ; Val - cit ; valine – citrulline dipeptide linker . D r ug D e s i gn , D e v e l op m en t and T he r ap y do w n l oaded f r o m h tt p s : / / www . do v ep r e ss . c o m / b y 54 . 70 . 40 . 11 on 26 - A ug - 2019 F o r pe r s ona l u s e on l y . Powered by TCPDF ( www . tcpdf . org ) 1 / 1 Drug Design , Development and Therapy 2017 : 11 submit your manuscript | www . dovepress . com Dovepress Dovepress 2272 Kalim et al is the second evaluated ADC in clinical studies , while the first one , MLN2704 , was restricted in 2008 due to less efficacy and limited peripheral neuro - therapy . 88 Internalization of this conjugate takes place through antigen - mediated pathways and trafficking to lysosome . Releases of MMAE synthetic dolastatin 10 analogs have taken place by cathepsin action in lysosome that results from inhibition of tubulin polymerization in prostatic cancer cells . 87 Gao et al reported Yajie prostate specific membrane antigen ( YPSMA ) - 1 - modified micelles that exhibited a rapid release behavior at endosomal / lysosomal pH . They introduced for the first time that both lysosome and endosomal escape exist for pH - sensitive micelles . The modified micelles enhance the cytotoxicity of the drug due to increase uptake of PSMA - positive prostate cancer cells . One possible approach of pH sensitivity to deliver drugs efficiently to PSMA - positive cells was also investigated . 89 inotuzumab ozogamicin ( CMC - 544 ) CMC - 544 is a second NAc - γ calicheamicin – conjugate that links via hydrazone linker and targets CD22 on B - cell malignancies . This ADC was found highly constant , effec - tive , dynamic , and precise both in vitro and in vivo . Phase III trials are being reported in various clinical trials as in acute lymphoblastic leukemia ( ALL ) , but due to lack of improve - ment and constancy in overall cell , it is withdrawn from this trial in CD22 - positive non - Hodgkin’s lymphoma . 90 , 91 Brenduximab vedotin ( Adcetris , SGN - 35 ) Adcetris is a conjugate of synthetic anti - tubulin agent MMAE ( dolstatin - 10 ) and chimeric CD30 antibody ( cAC10 ) linked by valine – citrulline dipeptide linker . 92 It ties with CD30 - positive cells and internalizes though CME , trafficked to the lysosome where discharge its conveying payload . MMAE binds with tubulin and inhibits its polymerization through G2 / M phase arrest in CD30 lymphoma cells . 75 Monotherapy of unconjugated anti - CD30 antibody ( cAC10 ) and drug con - jugate MMAE – brenduximab vedotin was investigated sepa - rately to examine the response rate . Insufficient 8 % response rate was recorded by using single antibody treatment , while complete eradication response was calculated by using ADC , prompted sharp approval by FDA in 2011 . 93 , 94 Ado - trastuzumab emtansine ( T - DM1 ) T - DM1 comprised trastuzumab antibody conjugated with maytansinoid by means of lysine by utilizing non - cleavable thioether linker , demonstrating promising viability against HER2 - positive metastatic cancer . 95 T - DM1 is internalized through receptor - mediated endocytosis and trafficked to lysosome to release its carrying drug . This intracellular release of maytansinoid prevents microtubule assembly and polymerization and disrupts HER3 / PI3K / AKT signaling pathway and Fc γ receptor - mediated engagement of effec - tor immune cells directed to mitotic arrest , apoptosis , and antibody - dependent cellular cytotoxicity . 96 , 97 Pre - clinical studies of T - DM1 demonstrate potent anti - proliferative activity both in vitro and in vivo as compared to trastuzumab alone . More interestingly , it was found effective against trastuzumab - resistant cells and also xenografts models . 95 Other studies indicate that T - DM1 also potentiates antibod - ies activity ( such as pertuzumab and B20 - 4 . 1 ) , chemothera - peutic agents ( such as carboplatin and 5 - fluorouracil ) , and kinase inhibitor molecules ( such as laptinib and PI3 kinase inhibitor ) against HER - 2 tumor cells . 98 These data led to Ado - trastuzumab emtansine being approved in 2013 by FDA to treat HER2 - positive metastatic breast cancer patients . 99 indatuximab ravtansine ( BT062 ) Indatuximab ravtansine ( Biotest AG Dreieich , Germany ) is composed of anti - CD138 mAb ( nBT062 ) conjugated through disulfide linker with maytansinoid DM4 toxin . CD138 was highly expressed in solid tumor and specifically on multiple myeloma cells . Internalization of indatuximab ravtansine occurs and processed further to release DM4 by the proteolytic activity of lysosome . DM4 inhibits tubu - lin polymerization and subsequently cell cycle arrest and tumor death . 95 , 96 Maytansinoid conjugates This conjugate includes different ADCs such as IMGN388 , 100 SAR3419 , 101 BIIB015 , 102 and nBT062 103 that utilized may - tansinoid disulfide cleavable linker . These conjugates are internalized through receptor - mediated endocytosis and trafficked to lysosome to release their active drugs . The maytansinoid conjugate binds to tubulin , disrupts the micro - tubule , and led to inhibition of cell division and ultimately result in cell death . 104 The clinical trials of BIIB015 in 2010 and IMGN 388 in 2011 were prematurely stopped in Phase I studies due to their limited scope and insufficient efficacy as shown in Table 2 . Lorvotuzumab mertansine Lorvotuzumab mertansine ( BB - 10901 , hu N901 - DM1 , or IMGN901 ) , a humanized version of the N901 antibody linked via a disulfide linker to DM1 , targeting CD56 in most small cell lung cancers ( SCLCs ) was reported by Whiteman et al 105 in detail . They also presented the potent activity of D r ug D e s i gn , D e v e l op m en t and T he r ap y do w n l oaded f r o m h tt p s : / / www . do v ep r e ss . c o m / b y 54 . 70 . 40 . 11 on 26 - A ug - 2019 F o r pe r s ona l u s e on l y . Powered by TCPDF ( www . tcpdf . org ) 1 / 1 Drug Design , Development and Therapy 2017 : 11 submit your manuscript | www . dovepress . com Dovepress Dovepress 2273 Intracellular trafficking of ADC lorvotuzumab mertansine in the combination of different agents to activate different killing pathways or sensitization of one agent killing by other . DM1 , synthetic derivative of maytansinioid , 106 is a potent anti - microtubule cytotoxic agent that binds to tubulin at a vinca alkaloid binding site that leads to inhibition of tubule assembly and proliferation , resulting in cell death . 107 Glembatumumab vedotin ( CDX - 011 ) CDX - 011 comprised of human IgG2 anti - gpNMB antibody – osteoactivin – and MMAE linked via cleavable valine – citrulline protease sensitive linker . Phase I / II study of this ADC was undertaken . 108 , 109 Vaklavas and Forero reported multiple steps that involved from endocytosis / trafficking to final release of this drug . Drug acquired access to a cell through receptor - mediated endocytosis followed by lyso - somal degradation of proteases , targeting mitotic spindles in metastatic breast cancer cells . 110 At present , CDX - 011 is in the premature stage in the clinical evaluation of melanoma and breast cancer . Conclusion and future prospects Antibody - based cancer treatment has been intensively studied and is well known that it has direct or indirect effects on a cancer cell . The potency is shown by these conjugates and different action performed by signal inhibition , limit - ing proliferation , apoptosis induction , cytotoxic drugs or radiation delivery , induction , and activation of immune cells and cytotoxicity , cell inhibition , or payload delivering to targeted area . 111 Recent approval of Adcetris and Kadcyla realized the potential benefits of ADCs . Our current review attempts to describe the developmental progress of ADC optimization , evaluation of extensive and better knowledge - related endocytosis , intracellular trafficking , and targeted action on tumor cells . Endocytosis and trafficking of ADCs performed the most critical role in affecting the target cells . Past investigations conclude that ADCs recognize their particular focuses on the cell surface , tie with the antigen , and intervene endocytosis that tile exceptional knowledge in ADCs viability . Protein machinery , lysosomal lumen nature , and linker procedure hold an imperative part in drug discharge that transported ADC to its focused area . Biologists are struggling to concentrate on the cell surface antigen , for specific attachment and further intracellular trafficking of ADCs . Recent studies indicate that an engineered antibody can be utilized to exploit the endocytosis pathway that gives a substantial inclination for future studies and better design of ADC . The experimental analysis provides knowledge of the intracellular process in greater aspects , dissolves recent divergences , and enhances our ability to select novel and efficient targets for antibody attachment and internalization of ADC . Additional fundamental research studies of tumor cell toxicity , target receptor modification , and cascade signaling analysis of receptor modulation by antibodies are needed to enrich the field of cancer immunotherapy and design better treatments for tumor therapy . Acknowledgments This work was supported by the National Nature Science Foundation of China ( grant no 81430081 ) and Special Program from the Department of Science and Technology , Zhejiang Province ( grant no 009C13041 ) , People’s Republic of China . Disclosure The authors report no conflicts of interest in this work . References 1 . Polakis P . Antibody drug conjugates for cancer therapy . Pharmacol Rev . 2016 ; 68 ( 1 ) : 3 – 19 . 2 . Kim MT , Chen Y , Marhoul J , Jacobson F . Statistical modeling of the drug load distribution on trastuzumab emtansine ( Kadcyla ) , a lysine - linked antibody drug conjugate . Bioconjug Chem . 2014 ; 25 ( 7 ) : 1223 – 1232 . 3 . Katz J , Janik JE , Younes A . Brentuximab vedotin ( SGN - 35 ) . Clin Cancer Res . 2011 ; 17 ( 20 ) : 6428 – 6436 . 4 . Bechhold H , Ehrlich P . Connections between chemical constitution and desinfection effect . Article on the study of “inner antisepsis” . Hoppe Seylers Z Physiol Chem . 1906 ; 47 ( 2 / 3 ) : 173 – 199 . 5 . Ehrlich P . Address in pathology , on chemiotherapy : delivered before the Seventeenth International Congress of Medicine . Br Med J . 1913 ; 2 ( 2746 ) : 353 – 359 . 6 . Kohler G , Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity ( Reprinted from Nature , vol 256 , 1975 ) . J Immunol . 2005 ; 174 ( 5 ) : 2453 – 2455 . 7 . Jordan MA , Wilson L . Microtubules as a target for anticancer drugs . Nat Rev Cancer . 2004 ; 4 ( 4 ) : 253 – 265 . 8 . Perego P , Corna E , De Cesare M , et al . Role of apoptosis and apoptosis - related genes in cellular response and antitumor efficacy of anthracy - clines . Curr Med Chem . 2001 ; 8 ( 1 ) : 31 – 37 . 9 . Naito K , Takeshita A , Shigeno K , et al . Calicheamicin - conjugated humanized anti - CD33 monoclonal antibody ( gemtuzumab ozogamicin , CMA - 676 ) shows cytocidal effect on CD33 - positive leukemia cell lines , but is inactive on P - glycoprotein - expressing sublines . Leukemia . 2000 ; 14 ( 8 ) : 1436 – 1443 . 10 . Ross PL , Wolfe JL . Physical and chemical stability of antibody drug conjugates : current status . J Pharm Sci . 2016 ; 105 ( 2 ) : 391 – 397 . 11 . McCombs JR , Owen SC . Antibody drug conjugates : design and selec - tion of linker , payload and conjugation chemistry . AAPS J . 2015 ; 17 ( 2 ) : 339 – 351 . 12 . Thomas A , Teicher BA , Hassan RT . Antibody - drug conjugates for cancer therapy . Lancet Oncol . 2016 ; 17 ( 6 ) : E254 – E262 . 13 . Sievers EL , Senter PD . Antibody - drug conjugates in cancer therapy . Annu Rev Med . 2013 ; 64 : 15 – 29 . 14 . Bander NH . Antibody - drug conjugate target selection : critical factors . Methods Mol Biol . 2013 ; 1045 : 29 – 40 . 15 . Conner SD , Schmid SL . Regulated portals of entry into the cell . Nature . 2003 ; 422 ( 6927 ) : 37 – 44 . D r ug D e s i gn , D e v e l op m en t and T he r ap y do w n l oaded f r o m h tt p s : / / www . do v ep r e ss . c o m / b y 54 . 70 . 40 . 11 on 26 - A ug - 2019 F o r pe r s ona l u s e on l y . Powered by TCPDF ( www . tcpdf . org ) 1 / 1 Drug Design , Development and Therapy 2017 : 11 submit your manuscript | www . dovepress . com Dovepress Dovepress 2274 Kalim et al 16 . Ritchie M , Tchistiakova L , Scott N . Implications of receptor - mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates . MAbs . 2013 ; 5 ( 1 ) : 13 – 21 . 17 . Li Y , Wang J , Wientjes MG , Au JLS . Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor . Adv Drug Deliv Rev . 2012 ; 64 ( 1 ) : 29 – 39 . 18 . Wang J , Lu Z , Wientjes MG , Au JLS . Delivery of siRNA therapeutics : Barriers and Carriers . AAPS J . 2010 ; 12 ( 4 ) : 492 – 503 . 19 . Wang J , Lu Z , Gao Y , Wientjes MG , Au JLS . Improving delivery and efficacy of nanomedicines in solid tumors : role of tumor priming . Nanomedicine . 2011 ; 6 ( 9 ) : 1605 – 1620 . 20 . Matsudaira H , Asakura T , Aoki K , et al . Target chemotherapy of anti - CD147 antibody - labeled liposome encapsulated GSH - DXR con - jugate on CD147 highly expressed carcinoma cells . Int J Oncol . 2010 ; 36 ( 1 ) : 77 – 83 . 21 . Hatakeyama H , Akita H , Maruyama K , Suhara T , Harashima H . Factors governing the in vivo tissue uptake of transferrin - coupled polyethylene glycol liposomes in vivo . Int J Pharm . 2004 ; 281 ( 1 – 2 ) : 25 – 33 . 22 . Mamot C , Drummond DC , Greiser U , et al . Epidermal growth factor receptor ( EGFR ) - targeted immunoliposomes mediate specific and efficient drug delivery to EGFR - and EGFRvIII - overexpressing tumor cells . Cancer Res . 2003 ; 63 ( 12 ) : 3154 – 3161 . 23 . Xiang G , Wu J , Lu Y , Liu Z , Lee RJ . Synthesis and evaluation of a novel ligand for folate - mediated targeting liposomes . Int J Pharm . 2008 ; 356 ( 1 – 2 ) : 29 – 36 . 24 . Khalil IA , Kogure K , Akita H , Harashima H . Uptake pathways and sub - sequent intracellular trafficking in nonviral gene delivery . Pharmacol Rev . 2006 ; 58 ( 1 ) : 32 – 45 . 25 . Huotari J , Helenius A . Endosome maturation . Embo J . 2011 ; 30 ( 17 ) : 3481 – 3500 . 26 . Mathivanan S , Ji H , Simpson RJ . Exosomes : extracellular organelles important in intercellular communication . J Proteomics . 2010 ; 73 ( 10 ) : 1907 – 1920 . 27 . Robinson MS . Forty years of clathrin - coated vesicles . Traffic . 2015 ; 16 ( 12 ) : 1210 – 1238 . 28 . Bitsikas V , Correa IR Jr , Nichols BJ . Clathrin - independent pathways do not contribute significantly to endocytic flux . Elife . 2014 ; 3 : e03970 . 29 . Parton RG . Caveolae meet endosomes : a stable relationship ? Dev Cell . 2004 ; 7 ( 4 ) : 458 – 460 . 30 . Doherty GJ , McMahon HT . Mechanisms of endocytosis . Annu Rev Biochem . 2009 ; 78 : 857 – 902 . 31 . Mercer J , Helenius A . Virus entry by macropinocytosis . Nat Cell Biol . 2009 ; 11 ( 5 ) : 510 – 520 . 32 . Mayor S , Parton RG , Donaldson JG . Clathrin - independent pathways of endocytosis . Cold Spring Harb Perspect Biol . 2014 ; 6 ( 6 ) : a016758 . 33 . Scita G , Di Fiore PP . The endocytic matrix . Nature . 2010 ; 463 ( 7280 ) : 464 – 473 . 34 . Zhang J , Zhang X , Liu G , et al . Intracellular trafficking network of protein nanocapsules : endocytosis , exocytosis and autophagy . Theranostics . 2016 ; 6 ( 12 ) : 2099 – 2113 . 35 . Anitei M , Hoflack B . Bridging membrane and cytoskeleton dynamics in the secretory and endocytic pathways . Nat Cell Biol . 2012 ; 14 ( 1 ) : 11 – 19 . 36 . Rusten TE , Vaccari T , Stenmark H . Shaping development with ESCRTs . Nat Cell Biol . 2012 ; 14 ( 1 ) : 38 – 45 . 37 . Coppola S , Cardarelli F , Pozzi D , et al . The role of cytoskeleton networks on lipid - mediated delivery of DNA . Ther Deliv . 2013 ; 4 ( 2 ) : 191 – 202 . 38 . Grant BD , Donaldson JG . Pathways and mechanisms of endocytic recycling . Nat Rev Mol Cell Biol . 2009 ; 10 ( 9 ) : 597 – 608 . 39 . Mukherjee S , Ghosh RN , Maxfield FR . Endocytosis . Physiol Rev . 1997 ; 77 ( 3 ) : 759 – 803 . 40 . Weisz OA . Acidification and protein traffic . Int Rev Cytol . 2003 ; 226 : 259 – 319 . 41 . Frick M , Bright NA , Riento K , Bray A , Merrified C , Nichols BJ . Coas - sembly of flotillins induces formation of membrane microdomains , membrane curvature , and vesicle budding . Current Biol . 2007 ; 17 ( 13 ) : 1151 – 1156 . 42 . Sabharanjak S , Sharma P , Parton RG , Mayor S . GPI - anchored proteins are delivered to recycling endosomes via a distinct cdc42 - regulated , clathrin - independent pinocytic pathway . Dev Cell . 2002 ; 2 ( 4 ) : 411 – 423 . 43 . Chadda R , Howes MT , Plowman SJ , Hancock JF , Parton RG , Mayor S . Cholesterol - sensitive Cdc42 activation regulates actin polymerization for endocytosis via the GEEC pathway . Traffic . 2007 ; 8 ( 6 ) : 702 – 717 . 44 . Schmid EM , McMahon HT . Integrating molecular and network biology to decode endocytosis . Nature . 2007 ; 448 ( 7156 ) : 883 – 888 . 45 . Brodsky FM , Chen CY , Knuehl C , Towler MC , Wakeham DE . Biological basket weaving : formation and function of clathrin - coated vesicles . Annu Rev Cell Dev Biol . 2001 ; 17 : 517 – 568 . 46 . Donaldson JG . Multiple roles for Arf6 : sorting , structuring , and signaling at the plasma membrane . J Biol Chem . 2003 ; 278 ( 43 ) : 41573 – 41576 . 47 . Parton RG , Simons K . The multiple faces of caveolae . Nat Rev Mol Cell Biol . 2007 ; 8 ( 3 ) : 185 – 194 . 48 . Pelkmans L , Burli T , Zerial M , Helenius A . Caveolin - stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic . Cell . 2004 ; 118 ( 6 ) : 767 – 780 . 49 . Llorente A , Rapak A , Schmid SL , van Deurs B , Sandvig K . Expression of mutant dynamin inhibits toxicity and transport of endocytosed ricin to the Golgi apparatus . J Cell Biol . 1998 ; 140 ( 3 ) : 553 – 563 . 50 . Kumari S , Mayor S . ARF1 is directly involved in dynamin - independent endocytosis . Nat Cell Biol . 2008 ; 10 ( 1 ) : 30 – 41 . 51 . Hanai A , Ohgi M , Yagi C , Ueda T , Shin HW , Nakayama K . Class I Arfs ( Arf1 and Arf3 ) and Arf6 are localized to the Flemming body and play important roles in cytokinesis . J Biochem . 2016 ; 159 ( 2 ) : 201 – 208 . 52 . Orth JD , Krueger EW , Weller SG , McNiven MA . A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization . Cancer Res . 2006 ; 66 ( 7 ) : 3603 – 3610 . 53 . Lanzetti L , Palamidessi A , Areces L , Scita G , Di Fiore PP . Rab5 is a signalling GTPase involved in actin remodelling by receptor tyrosine kinases . Nature . 2004 ; 429 ( 6989 ) : 309 – 314 . 54 . Casi G , Neri D . Antibody - drug conjugates : basic concepts , examples and future perspectives . J Control Release . 2012 ; 161 ( 2 ) : 422 – 428 . 55 . Carter PJ , Senter PD . Antibody - drug conjugates for cancer therapy . Cancer J . 2008 ; 14 ( 3 ) : 154 – 169 . 56 . Ducry L , Stump B . Antibody - drug conjugates : linking cytotoxic pay - loads to monoclonal antibodies . Bioconjug Chem . 2010 ; 21 ( 1 ) : 5 – 13 . 57 . Doronina SO , Mendelsohn BA , Bovee TD , et al . Enhanced activity of monomethyl auristatin F through monoclonal antibody delivery : effects of linker technology on efficacy and toxicity . Bioconjug Chem . 2006 ; 17 ( 1 ) : 114 – 124 . 58 . Dubowchik GM , Firestone RA , Padilla L , et al . Cathepsin B - labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates : model studies of enzymatic drug release and antigen - specific in vitro anticancer activity . Bioconjug Chem . 2002 ; 13 ( 4 ) : 855 – 869 . 59 . Sanderson RJ , Hering MA , James SF , et al . In vivo drug - linker stability of an anti - CD30 dipeptide - linked auristatin immunoconjugate . Clin Cancer Res . 2005 ; 11 ( 2 ) : 843 – 852 . 60 . Phillips GDL , Li G , Dugger DL , et al . Targeting HER2 - positive breast cancer with trastuzumab - DM1 , an antibody - cytotoxic drug conjugate . Cancer Res . 2008 ; 68 ( 22 ) : 9280 – 9290 . 61 . Feld J , Barta SK , Schinke C , Braunschweig I , Zhou Y , Verma AK . Linked - in : design and efficacy of antibody drug conjugates in oncology . Oncotarget . 2013 ; 4 ( 3 ) : 397 – 412 . 62 . Nolting B . Linker technologies for antibody drug conjugates . Methods Mol Biol . 2013 ; 1045 : 71 – 100 . 63 . Gerber H - P , Senter PD , Grewal IS . Antibody drug - conjugates targeting the tumor vasculature current and future developments . MAbs . 2009 ; 1 ( 3 ) : 247 – 253 . 64 . Polakis P . Arming antibodies for cancer therapy . Curr Opin Pharmacol . 2005 ; 5 ( 4 ) : 382 – 387 . 65 . Kovtun YV , Audette CA , Ye YM , et al . Antibody - drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen . Cancer Res . 2006 ; 66 ( 6 ) : 3214 – 3221 . D r ug D e s i gn , D e v e l op m en t and T he r ap y do w n l oaded f r o m h tt p s : / / www . do v ep r e ss . c o m / b y 54 . 70 . 40 . 11 on 26 - A ug - 2019 F o r pe r s ona l u s e on l y . Powered by TCPDF ( www . tcpdf . org ) 1 / 1 Drug Design , Development and Therapy 2017 : 11 submit your manuscript | www . dovepress . com Dovepress Dovepress 2275 Intracellular trafficking of ADC 66 . Chari RVJ . Targeted cancer therapy : conferring specificity to cytotoxic drugs . Acc Chem Res . 2008 ; 41 ( 1 ) : 98 – 107 . 67 . Erickson HK , Widdison WC , Mayo MF , et al . Tumor delivery and in vivo processing of disulfide - linked and thioether - linked antibody - maytansinoid conjugates . Bioconjug Chem . 2010 ; 21 ( 1 ) : 84 – 92 . 68 . Okeley NM , Miyamoto JB , Zhang X , et al . Intracellular activation of SGN - 35 , a potent anti - CD30 antibody - drug conjugate . Clin Cancer Res . 2010 ; 16 ( 3 ) : 888 – 897 . 69 . Shen B - Q , Bumbaca D , Saad O , et al . Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine ( T - DM1 ) : an emphasis on preclinical and clinical catabolism . Curr Drug Metab . 2012 ; 13 ( 7 ) : 901 – 910 . 70 . Kung Sutherland MS , Walter RB , Jeffrey SC , et al . SGN - CD33A : a novel CD33 - targeting antibody - drug conjugate using a pyrroloben - zodiazepine dimer is active in models of drug - resistant AML . Blood . 2013 ; 122 ( 8 ) : 1455 – 1463 . 71 . Lyon RP , Setter JR , Bovee TD , et al . Self - stabilizing ADCs : antibody - drug conjugates prepared with maleimido drug - linkers that catalyze their own thiosuccinimide ring hydrolysis . Cancer Res . 2013 ; 73 ( 8 ) : ( Suppl 1 ) . 72 . King HD , Yurgaitis D , Willner D , et al . Monoclonal antibody conjugates of doxorubicin prepared with branched linkers : a novel method for increasing the potency of doxorubicin immunoconjugates . Bioconjug Chem . 1999 ; 10 ( 2 ) : 279 – 288 . 73 . Li Q , Tang Q , Zhang P , et al . Human epidermal growth factor receptor - 2 antibodies enhance the specificity and anticancer activity of light - sensitive doxorubicin - labeled liposomes . Biomaterials . 2015 ; 57 : 1 – 11 . 74 . Rowe JM , Lowenberg B . Gemtuzumab ozogamicin in acute myeloid leukemia : a remarkable saga about an active drug . Blood . 2013 ; 121 ( 24 ) : 4838 – 4841 . 75 . Sutherland MSK , Sanderson RJ , Gordon KA , et al . Lysosomal traffick - ing and cysteine protease metabolism confer target - specific cytotoxic - ity by peptide - linked anti - CD30 - auristatin conjugates . J Biol Chem . 2006 ; 281 ( 15 ) : 10540 – 10547 . 76 . Hamann PR , Hinman LM , Beyer CF , et al . A calicheamicin conjugate with a fully humanized anti - MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts . Bioconjug Chem . 2005 ; 16 ( 2 ) : 354 – 360 . 77 . Ingle GS , Chan P , Elliott JM , et al . High CD21 expression inhibits internalization of anti - CD19 antibodies and cytotoxicity of an anti - CD19 - drug conjugate . Br J Haematol . 2008 ; 140 ( 1 ) : 46 – 58 . 78 . Law CL , Gordon KA , Toki BE , et al . Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti - CD70 antibody - drug conjugates . Cancer Res . 2006 ; 66 ( 4 ) : 2328 – 2337 . 79 . Law CL , Cerveny CG , Gordon KA , et al . Efficient elimination of B - lineage lymphomas by anti - CD20 - auristatin conjugates . Clin Cancer Res . 2004 ; 10 ( 23 ) : 7842 – 7851 . 80 . Li ZH , Zhang Q , Wang HB , et al . Preclinical studies of targeted therapies for CD20 - positive B lymphoid malignancies by Ofatu - mumab conjugated with auristatin . Invest New Drugs . 2014 ; 32 ( 1 ) : 75 – 86 . 81 . Pan L - Q , Wang H - B , Xie Z - M , et al . Novel conjugation of tumor - necrosis - factor - related apoptosis - inducing ligand ( TRAIL ) with monomethyl auristatin E for efficient antitumor drug delivery . Adv Mater Deerfield . 2013 ; 25 ( 34 ) : 4718 – 4722 . 82 . Smith LM , Nesterova A , Alley SC , Torgov MY , Carter PJ . Potent cyto - toxicity of an auristatin - containing antibody - drug conjugate targeting melanoma cells expressing melanotransferrin / p97 . Mol Cancer Ther . 2006 ; 5 ( 6 ) : 1474 – 1482 . 83 . Austin CD , Wen XH , Gazzard L , Nelson C , Scheller RH , Scales SJ . Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide - based antibody - drug conjugates . Proc Natl Acad Sci U S A . 2005 ; 102 ( 50 ) : 17987 – 17992 . 84 . Walter RB , Raden BW , Kamikura DM , Cooper JA , Bernstein ID . Influence of CD33 expression levels and ITIM - dependent internaliza - tion on gemtuzumab ozogamicin - induced cytotoxicity . Blood . 2005 ; 105 ( 3 ) : 1295 – 1302 . 85 . Jedema I , Barge RMY , van der Velden VHJ , et al . Internalization and cell cycle - dependent killing of leukemic cells by gemtuzumab ozogamicin : rationale for efficacy in CD33 - negative malignancies with endocytic capacity . Leukemia . 2004 ; 18 ( 2 ) : 316 – 325 . 86 . Maass KF , Kulkarni C , Betts AM , Wittrup KD . Determination of cel - lular processing rates for a trastuzumab - maytansinoid antibody - drug conjugate ( ADC ) highlights key parameters for ADC design . AAPS J . 2016 ; 18 ( 3 ) : 635 – 646 . 87 . Wang X , Ma D , Olson WC , Heston WDW . In vitro and in vivo responses of advanced prostate tumors to PSMA ADC , an auristatin - conjugated antibody to prostate - specific membrane antigen . Mol Cancer Ther . 2011 ; 10 ( 9 ) : 1728 – 1739 . 88 . Galsky MD , Eisenberger M , Moore - Cooper S , et al . Phase I trial of the prostate - specific membrane antigen directed immunoconjugate MLN2704 in patients with progressive metastatic castration - resistant prostate cancer . J Clin Oncol . 2008 ; 26 ( 13 ) : 2147 – 2154 . 89 . Gao Y , Li Y , Li Y , et al . PSMA - mediated endosome escape - acceler - ating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking . Nanoscale . 2015 ; 7 ( 2 ) : 597 – 612 . 90 . Advani A , Coiffier B , Czuczman MS , et al . Safety , pharmacokinetics , and preliminary clinical activity of inotuzumab ozogamicin , a novel immunoconjugate for the treatment of B - cell non - Hodgkin’s lymphoma : results of a phase I study . J Clin Oncol . 2010 ; 28 ( 12 ) : 2085 – 2093 . 91 . Kantarjian H , Thomas D , Jorgensen J , et al . Inotuzumab ozogamicin , an anti - CD22 - calecheamicin conjugate , for refractory and relapsed acute lymphocytic leukaemia : a phase 2 study . Lancet Oncol . 2012 ; 13 ( 4 ) : 403 – 411 . 92 . Francisco JA , Cerveny CG , Meyer DL , et al . cAC10 - vcMMAE , an anti - CD30 - monomethyl auristatin E conjugate with potent and selec - tive antitumor activity . Blood . 2003 ; 102 ( 4 ) : 1458 – 1465 . 93 . Younes A , Bartlett NL , Leonard JP , et al . Brentuximab vedotin ( SGN - 35 ) for relapsed CD30 - positive lymphomas . N Engl J Med . 2010 ; 363 ( 19 ) : 1812 – 1821 . 94 . Younes A , Gopal AK , Smith SE , et al . Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma . J Clin Oncol . 2012 ; 30 ( 18 ) : 2183 – 2189 . 95 . Lewis Phillips GD , Li G , Dugger DL , et al . Targeting HER2 - positive breast cancer with trastuzumab - DM1 , an antibody - cytotoxic drug conjugate . Cancer Res . 2008 ; 68 ( 22 ) : 9280 – 9290 . 96 . Barok M , Joensuu H , Isola J . Trastuzumab emtansine : mechanisms of action and drug resistance . Breast Cancer Res . 2014 ; 16 ( 2 ) : 209 . 97 . LoRusso PM , Weiss D , Guardino E , Girish S , Sliwkowski MX . Tras - tuzumab emtansine : a unique antibody - drug conjugate in development for human epidermal growth factor receptor 2 - positive cancer . Clin Cancer Res . 2011 ; 17 ( 20 ) : 6437 – 6447 . 98 . Phillips GDL , Fields CT , Crocker L , et al . Potent anti - tumor activity of trastuzumab - DM1 antibody - drug conjugate in combination with cytotoxic chemotherapeutic agents , antibodies or small molecule kinase inhibitors . Proc Am Assoc Cancer Res Annu Meet . 2008 ; 49 : 502 . 99 . Chari RVJ , Miller ML , Widdison WC . Antibody - drug conjugates : an emerging concept in cancer therapy . Angew Chem Int Ed Engl . 2014 ; 53 ( 15 ) : 3796 – 3827 . 100 . Vater CA , Manning C , Millar H , et al . Anti - tumor efficacy of the integrin - targeted immunoconjugate IMGN388 in preclinical models . EJC Suppl . 2008 ; 6 ( 12 ) : 167 – 168 . 101 . Blanc V , Bousseau A , Caron A , Carrez C , Lutz RJ , Lambert JM . SAR3419 : an anti - CD19 - maytansinoid immunoconjugate for the treatment of B - cell malignancies . Clin Cancer Res . 2011 ; 17 ( 20 ) : 6448 – 6458 . 102 . Kelly RK , Olson DL , Sun Y , et al . An antibody - cytotoxic conjugate , BIIB015 , is a new targeted therapy for Cripto positive tumours . Eur J Cancer . 2011 ; 47 ( 11 ) : 1736 – 1746 . 103 . Ikeda H , Hideshima T , Fulciniti M , et al . The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cyto - toxicity against CD138 - positive multiple myeloma cells in vitro and in vivo . Clin Cancer Res . 2009 ; 15 ( 12 ) : 4028 – 4037 . D r ug D e s i gn , D e v e l op m en t and T he r ap y do w n l oaded f r o m h tt p s : / / www . do v ep r e ss . c o m / b y 54 . 70 . 40 . 11 on 26 - A ug - 2019 F o r pe r s ona l u s e on l y . Powered by TCPDF ( www . tcpdf . org ) 1 / 1 Drug Design , Development and Therapy Publish your work in this journal Submit your manuscript here : http : / / www . dovepress . com / drug - design - development - and - therapy - journal Drug Design , Development and Therapy is an international , peer - reviewed open - access journal that spans the spectrum of drug design and development through to clinical applications . Clinical outcomes , patient safety , and programs for the development and effective , safe , and sustained use of medicines are the features of the journal , which has also been accepted for indexing on PubMed Central . The manu - script management system is completely online and includes a very quick and fair peer - review system , which is all easy to use . Visit http : / / www . dovepress . com / testimonials . php to read real quotes from published authors . Drug Design , Development and Therapy 2017 : 11 submit your manuscript | www . dovepress . com Dovepress Dovepress Dovepress 2276 Kalim et al 104 . Erickson HK , Park PU , Widdison WC , et al . Antibody - maytansinoid conjugates are activated in targeted cancer cells by lysosomal degrada - tion and linker - dependent intracellular processing . Cancer Res . 2006 ; 66 ( 8 ) : 4426 – 4433 . 105 . Whiteman KR , Johnson HA , Mayo MF , et al . Lorvotuzumab mer - tansine , a CD56 - targeting antibody - drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models . MAbs . 2014 ; 6 ( 2 ) : 556 – 566 . 106 . Berdeja JG . Lorvotuzumab mertansine : antibody - drug - conjugate for CD56 ( + ) multiple myeloma . Front Biosci ( Landmark Ed ) . 2014 ; 19 : 163 – 170 . 107 . Lutz RJ , Whiteman KR . Antibody - maytansinoid conjugates for the treatment of myeloma . MAbs . 2009 ; 1 ( 6 ) : 548 – 551 . 108 . Keir CH , Vahdat LT . The use of an antibody drug conjugate , glem - batumumab vedotin ( CDX - 011 ) , for the treatment of breast cancer . Expert Opin Biol Ther . 2012 ; 12 ( 2 ) : 259 – 263 . 109 . Naumovski L , Junutula JR . Glembatumumab vedotin , a conjugate of an anti - glycoprotein non - metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer . Curr Opin Mol Ther . 2010 ; 12 ( 2 ) : 248 – 257 . 110 . Vaklavas C , Forero A . Management of metastatic breast cancer with second - generation antibody - drug conjugates : focus on glembatu - mumab vedotin ( CDX - 011 , CR011 - vcMMAE ) . BioDrugs . 2014 ; 28 ( 3 ) : 253 – 263 . 111 . Scott AM , Allison JP , Wolchok JD . Monoclonal antibodies in cancer therapy . Cancer Immun . 2012 ; 12 : 14 . 112 . Lambert JM . Antibody - maytansinoid conjugates : a new strategy for the treatment of cancer . Drugs Future . 2010 ; 35 ( 6 ) : 471 – 480 . 113 . Ikemoto N , Kumar RA , Ling TT , Ellestad GA , Danishefsky SJ , Patel DJ . Calicheamicin - DNA complexes – warhead alignment and saccharide recognition of the minor - groove . Proc Natl Acad Sci U S A . 1995 ; 92 ( 23 ) : 10506 – 10510 . 114 . Boger DL , Johnson DS . CC - 1065 and the duocarmycins – unraveling the keys to a new class of naturally derived DNA alkylating - agents . Proc Natl Acad Sci U S A . 1995 ; 92 ( 9 ) : 3642 – 3649 . 115 . Abal M , Andreu JM , Barasoain I . Taxanes : microtubule and centrosome targets , and cell cycle dependent mechanisms of action . Curr Cancer Drug Targets . 2003 ; 3 ( 3 ) : 193 – 203 . 116 . Minotti G , Menna P , Salvatorelli E , Cairo G , Gianni L . Anthracyclines : molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity . Pharmacol Rev . 2004 ; 56 ( 2 ) : 185 – 229 . 117 . Monneret C . Recent developments in the field of antitumour anthra - cyclines . Eur J Med Chem . 2001 ; 36 ( 6 ) : 483 – 493 . 118 . Dornan D , Bennett F , Chen Y , et al . Therapeutic potential of an anti - CD79b antibody - drug conjugate , anti - CD79b - vc - MMAE , for the treatment of non - Hodgkin lymphoma . Blood . 2009 ; 114 ( 13 ) : 2721 – 2729 . 119 . Li D , Poon KA , Yu S - F , et al . DCDT2980S , an anti - CD22 - monomethyl auristatin E antibody - drug conjugate , is a potential treatment for non - Hodgkin lymphoma . Mol Cancer Ther . 2013 ; 12 ( 7 ) : 1255 – 1265 . 120 . Mayo MF , Leung AP , Wang L , et al . In vivo stability in mice of SAR566658 ( huDS6 - DM4 ) , an immunoconjugate targeting solid tumours . EJC Suppl . 2008 ; 6 ( 12 ) : 169 . 121 . Petrul HM , Schatz CA , Kopitz CC , et al . Therapeutic mechanism and efficacy of the antibody - drug conjugate BAY 79 - 4620 targeting human carbonic anhydrase 9 . Mol Cancer Ther . 2012 ; 11 ( 2 ) : 340 – 349 . 122 . Bendell J , Blumenschein G , Zinner R , et al . First - in - human phase I dose escalation study of a novel anti - mesothelin antibody drug conjugate ( ADC ) , BAY 94 - 9343 , in patients with advanced solid tumors . Cancer Res . 2013 ; 73 ( 8 ) : ( Suppl 1 ) . 123 . Thompson JA , Forero - Torres A , Heath EI , et al . The effect of SGN - 75 , a novel antibody - drug conjugate ( ADC ) , in treatment of patients with renal cell carcinoma ( RCC ) or non - Hodgkin lymphoma ( NHL ) : a phase I study . J Clin Oncol . 2011 ; 29 ( 15 ) : ( Suppl S ) . 124 . Oflazoglu E , Stone IJ , Gordon K , et al . Potent anticarcinoma activity of the humanized anti - CD70 antibody h1F6 conjugated to the tubu - lin inhibitor auristatin via an uncleavable linker . Clin Cancer Res . 2008 ; 14 ( 19 ) : 6171 – 6180 . 125 . Govindan SV , Cardillo TM , Moon S - J , Hansen HJ , Goldenberg DM . CEACAM5 - targeted therapy of human colonic and pancreatic can - cer xenografts with potent labetuzumab - SN - 38 immunoconjugates . Clin Cancer Res . 2009 ; 15 ( 19 ) : 6052 – 6061 . 126 . Thevanayagam L , Bell A , Chakraborty I , et al . Novel detection of DNA - alkylated adducts of antibody - drug conjugates with poten - tially unique preclinical and biomarker applications . Bioanalysis . 2013 ; 5 ( 9 ) : 1073 – 1081 . 127 . Kurkjian C , LoRusso P , Sankhala KK , et al . A phase I , first - in - human study to evaluate the safety , pharmacokinetics ( PK ) , and pharmaco - dynamics ( PD ) of IMGN853 in patients ( Pts ) with epithelial ovarian cancer ( EOC ) and other FOLR1 - positive solid tumors . J Clin Oncol . 2013 ; 31 ( 15 ) : ( Suppl S ) . 128 . Setiady YY , Park PU , Ponte JF , et al . Development of a novel antibody - maytansinoid conjugate , IMGN289 , for the treatment of EGFR - expressing solid tumors . Cancer Res . 2013 ; 73 ( 8 ) : ( Suppl 1 ) . 129 . Adair JR , Howard PW , Hartley JA , Williams DG , Chester KA . Antibody - drug conjugates – a perfect synergy . Expert Opin Biol Ther . 2012 ; 12 ( 9 ) : 1191 – 1206 . 130 . Beckwith KA , Frissora FW , Stefanovski MR , et al . The CD37 - targeted antibody - drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model . Leukemia . 2014 ; 28 ( 7 ) : 1501 – 1510 . 131 . Gudas JM , An Z , Morrison RK , et al . ASG - 5ME is a novel antibody drug conjugate ( ADC ) for treating prostate cancers . Proc Am Assoc Cancer Res Annu Meet . 2010 ; 51 : 1066 . D r ug D e s i gn , D e v e l op m en t and T he r ap y do w n l oaded f r o m h tt p s : / / www . do v ep r e ss . c o m / b y 54 . 70 . 40 . 11 on 26 - A ug - 2019 F o r pe r s ona l u s e on l y . Powered by TCPDF ( www . tcpdf . org ) 1 / 1